Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)

• Status: Completed
• Trial end date: 2008-09-01

Summary

The present clinical trial will investigate the safety and efficacy of a sequential preoperative therapy with Epirubicin/Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab in patients with HER-2 overexpression primary breast cancer.

• Phase: Phase 2

Details

• Lead Sponsor: German Breast Group
• Collaborator: AGO Study Group
• Treatments: Albumin-Bound Paclitaxel; Cyclophosphamide; Epirubicin; Paclitaxel; Trastuzumab